Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CLOUDBREAK-B Soares Total 70%+ in 6 Days as Core Product CBT-009 Secures Patents in JP/ Europe
Recommend 1 Positive 1 Negative 1 |
||||
|
||||
|
CLOUDBREAK-B (02592.HK) continued its uptrend from the past 5 days, and opened 1.2% lower this morning (28th) before rebounding in the morning session. It last printed at $8.15, surging 12.26%, with a trading volume of 3.1011 million shares, involving $24.5992 million. Its current price is 73.4% higher than the closing price of $4.7 last Thursday (20th). The Group's wholly-owned US subsidiary, ADS USA, has successfully obtained the grants of patents from the Japan Patent Office (JPO) and the European Patent Office (EPO) in respect of one of the Group's core products, CBT-009, as announced by the Group. It is anticipated that the Group will be able to initiate collaboration with major pharmaceutical corporations to establish licensing arrangements for the manufacture, development and distribution of CBT-009 in both Japan and Europe. CBT-009 is a novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia in children and adolescents aged 5 to 19 years. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
